ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 235,11
0,78%
Dow Jones
44 910,65
0,42%
DAX
19 626,45
1,05%
Brent Oil
71,98
-0,08%
Bitcoin
96 167,73
-1,35%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) Actualités

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OKYO
DateHeureSourceTitreSymboleSociété
26/11/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
26/11/202413h00GlobeNewswire Inc.OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNASDAQ:OKYOOKYO Pharma Ltd
30/10/202412h00GlobeNewswire Inc.OKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceNASDAQ:OKYOOKYO Pharma Ltd
23/10/202413h00GlobeNewswire Inc.OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
16/10/202413h00GlobeNewswire Inc.OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
10/09/202413h00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
27/08/202413h00GlobeNewswire Inc.OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
23/08/202415h00GlobeNewswire Inc.OKYO Pharma CEO Interview to Air on Bloomberg TVNASDAQ:OKYOOKYO Pharma Ltd
15/08/202418h13GlobeNewswire Inc.OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:OKYOOKYO Pharma Ltd
13/08/202422h30Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:OKYOOKYO Pharma Ltd
06/08/202413h00GlobeNewswire Inc.OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseNASDAQ:OKYOOKYO Pharma Ltd
31/07/202423h00Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:OKYOOKYO Pharma Ltd
11/07/202413h00GlobeNewswire Inc.OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101NASDAQ:OKYOOKYO Pharma Ltd
10/07/202413h00GlobeNewswire Inc.OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
08/05/202413h00GlobeNewswire Inc.OKYO Pharma Announces Participation in May 2024 Investor ConferencesNASDAQ:OKYOOKYO Pharma Ltd
30/04/202413h00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)NASDAQ:OKYOOKYO Pharma Ltd
09/04/202401h00GlobeNewswire Inc.OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024NASDAQ:OKYOOKYO Pharma Ltd
02/04/202413h00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryNASDAQ:OKYOOKYO Pharma Ltd
22/03/202412h00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101NASDAQ:OKYOOKYO Pharma Ltd
21/03/202412h00GlobeNewswire Inc.OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialNASDAQ:OKYOOKYO Pharma Ltd
20/03/202412h00GlobeNewswire Inc.OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventNASDAQ:OKYOOKYO Pharma Ltd
09/02/202413h36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
31/01/202413h00GlobeNewswire Inc.OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardNASDAQ:OKYOOKYO Pharma Ltd
08/01/202413h00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
05/01/202415h30GlobeNewswire Inc.OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024NASDAQ:OKYOOKYO Pharma Ltd
20/12/202323h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OKYOOKYO Pharma Ltd
04/12/202313h00GlobeNewswire Inc.OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol VisitNASDAQ:OKYOOKYO Pharma Ltd
31/10/202312h00GlobeNewswire Inc.OKYO Pharma Announces $5.84 Million Cash Raise and Payables ReductionNASDAQ:OKYOOKYO Pharma Ltd
09/10/202317h34InvestorsHub NewsWireOKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP")NASDAQ:OKYOOKYO Pharma Ltd
09/10/202313h00GlobeNewswire Inc.OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)NASDAQ:OKYOOKYO Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:OKYO

Dernières Valeurs Consultées

EU
NSC000000032
Dummy Utp Historical Data
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés

BLACK FRIDAY

ADVFN

Célébrons nos 25 ans Est 1999-2024

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Cours Euronext en temps réel et illimités sur le site. Carnet d'ordres Euronext en direct